The surge in global cancer cases is raising serious concerns among experts. A recent study published in Monday in Cancer, a ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Mammogram providers are now federally required to tell their patients about their breast density. The new U.S. Food and Drug ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

The Food and Drug Administration issued a rule in March 2023 that requires health care professionals to notify people if they have dense breasts. Studies have shown dense breast tissue can make it ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Targeting two receptors instead of the one targeted by fezolinetant, the new elinzanetant did not show the liver safety ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Due to advances in prevention, early detection and treatment, the overall cancer death rate in the U.S. fell by 33% between ...

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West ...